Compare Wockhardt with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs TORRENT PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT TORRENT PHARMA WOCKHARDT/
TORRENT PHARMA
 
P/E (TTM) x -47.9 39.5 - View Chart
P/BV x 1.1 8.6 12.4% View Chart
Dividend Yield % 0.0 0.7 0.5%  

Financials

 WOCKHARDT   TORRENT PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
TORRENT PHARMA
Mar-19
WOCKHARDT/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0121,964 51.5%   
Low Rs5321,245 42.7%   
Sales per share (Unadj.) Rs355.9453.4 78.5%  
Earnings per share (Unadj.) Rs-60.325.8 -233.8%  
Cash flow per share (Unadj.) Rs-46.862.3 -75.1%  
Dividends per share (Unadj.) Rs0.0117.00 0.1%  
Dividend yield (eoy) %01.1 0.1%  
Book value per share (Unadj.) Rs257.8279.2 92.3%  
Shares outstanding (eoy) m110.63169.22 65.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.5 61.3%   
Avg P/E ratio x-12.862.2 -20.6%  
P/CF ratio (eoy) x-16.525.8 -64.1%  
Price / Book Value ratio x3.05.7 52.1%  
Dividend payout %065.9 -0.0%   
Avg Mkt Cap Rs m85,379271,513 31.4%   
No. of employees `0006.313.6 46.0%   
Total wages/salary Rs m9,37114,038 66.8%   
Avg. sales/employee Rs Th6,295.05,642.6 111.6%   
Avg. wages/employee Rs Th1,498.31,032.4 145.1%   
Avg. net profit/employee Rs Th-1,066.3320.9 -332.3%   
INCOME DATA
Net Sales Rs m39,36976,728 51.3%  
Other income Rs m1,202571 210.7%   
Total revenues Rs m40,57177,299 52.5%   
Gross profit Rs m1819,831 0.1%  
Depreciation Rs m1,4956,177 24.2%   
Interest Rs m2,5555,038 50.7%   
Profit before tax Rs m-2,8309,187 -30.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582-3,570 100.3%   
Tax Rs m2571,254 20.5%   
Profit after tax Rs m-6,6694,363 -152.8%  
Gross profit margin %025.8 0.2%  
Effective tax rate %-9.113.6 -66.6%   
Net profit margin %-16.95.7 -297.9%  
BALANCE SHEET DATA
Current assets Rs m33,79650,375 67.1%   
Current liabilities Rs m26,91751,653 52.1%   
Net working cap to sales %17.5-1.7 -1,049.2%  
Current ratio x1.31.0 128.7%  
Inventory Days Days7992 86.2%  
Debtors Days Days8968 130.7%  
Net fixed assets Rs m39,66483,648 47.4%   
Share capital Rs m553846 65.4%   
"Free" reserves Rs m27,96846,397 60.3%   
Net worth Rs m28,52247,244 60.4%   
Long term debt Rs m21,73139,129 55.5%   
Total assets Rs m81,620141,209 57.8%  
Interest coverage x-0.12.8 -3.8%   
Debt to equity ratio x0.80.8 92.0%  
Sales to assets ratio x0.50.5 88.8%   
Return on assets %-5.06.7 -75.7%  
Return on equity %-23.49.2 -253.2%  
Return on capital %-7.712.3 -62.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80722,103 44.4%   
Fx outflow Rs m1,7895,522 32.4%   
Net fx Rs m8,01916,581 48.4%   
CASH FLOW
From Operations Rs m68417,981 3.8%  
From Investments Rs m6,302-2,413 -261.2%  
From Financial Activity Rs m-7,695-13,145 58.5%  
Net Cashflow Rs m-6642,380 -27.9%  

Share Holding

Indian Promoters % 74.5 71.5 104.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 7.0 32.8%  
FIIs % 7.7 12.6 61.1%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 8.8 175.0%  
Shareholders   67,757 26,511 255.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare WOCKHARDT With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

The Triple Digit Return Opportunity in this Market

Jun 24, 2020

Rahul Shah on stocks with potentially triple digit returns.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Jul 3, 2020 03:35 PM

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS